In September 2015, the patient was first diagnosed with stage IIb (cT2N1M0) ER+/HER2- BC and underwent neoadjuvant therapy with fulvestrant plus anastrozole in a clinical trial, followed by surgery, adjuvant chemotherapy, radiation therapy, and anastrozole as maintenance treatment. The gene discussed is ERBB2; the disease is breast cancer.